title: Intense 201 Tl uptake in giant-cell tumour of bone.
abstract: The aim of this study was to determine the characteristics and clinical usefulness of 201Tl scintigraphy in giant-cell tumour of bone (GCT). Twenty-one patients with histopathologically proven benign GCT (22 lesions; 18 primary and four recurrent) underwent 201Tl scintigraphy. We also studied conventional osteosarcoma (10 lesions), a very common primary malignant bone tumour; and chordoma in the sacrum (four lesions), an entity requiring differential diagnosis from GCT of the sacrum. Early and delayed planar imaging was performed at 15 min (early) and 3 h (delayed) after the intravenous injection of 201Tl chloride (111 MBq). The Tl uptake ratio was calculated by dividing the count density of the tumour region of interest (ROI) by that of the background ROI. All GCT lesions showed increased Tl uptake in both early and delayed images. The mean Tl uptake ratios of primary GCT were 4.7 (range, 2.0-11.1) in the early images and 2.2 (range, 1.4-3.6) in the delayed images, and those of recurrent lesions were 5.8 (range, 2.4-11.5) in the early images and 2.7 (range, 2.0-4.3) in the delayed images. There were no significant differences between the uptake ratios in GCT and osteosarcoma, but the values of GCT tended to be higher than those of osteosarcoma, 3.1 (range, 1.7-4.4) in the early images and 1.8 (range, 1.3-2.3) in the delayed images. Chordoma did not show appreciable Tl uptake: the uptake ratio was 1.19 (range, 0.98-1.5) in the early images and 1.1 (range, 1.0-1.3) in the delayed images. In GCT, a benign lesion, Tl scintigraphy demonstrated marked uptake in both primary and recurrent lesions with no exceptions, precluding the use of Tl scintigraphy for the differential diagnosis of GCT from malignant tumours. However, the Tl scintigraphy can be used for excluding GCT when no lesional Tl uptake is observed, and diagnosing recurrent lesions on post-operative follow-up.
authors.affiliation: Department of Nuclear Medicine, Kanazawa University School of Medicine, Japan. higuchi@med.kanazawa-u.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Higuchi
authors.forename: J
authors.initials: J
authors.lastname: Taki
authors.forename: H
authors.initials: H
authors.lastname: Sumiya
authors.forename: S
authors.initials: S
authors.lastname: Kinuya
authors.forename: H
authors.initials: H
authors.lastname: Bunko
authors.forename: A
authors.initials: A
authors.lastname: Nonomura
authors.forename: H
authors.initials: H
authors.lastname: Tsuchiya
authors.forename: N
authors.initials: N
authors.lastname: Tonami
mesh_terms: D000328:Adult; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D002817:Chordoma / Q000000981:diagnostic imaging* / Q000378:metabolism; D003937:Diagnosis, Differential; D005260:Female; D018212:Giant Cell Tumor of Bone / Q000000981:diagnostic imaging* / Q000378:metabolism; D006801:Humans; D007867:Leg Bones / Q000000981:diagnostic imaging* / Q000378:metabolism; D008297:Male; D012516:Osteosarcoma; D011237:Predictive Value of Tests; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012189:Retrospective Studies; D012447:Sacrum / Q000000981:diagnostic imaging* / Q000378:metabolism; D012680:Sensitivity and Specificity; D013793:Thallium / Q000493:pharmacokinetics
chemical_list: D019275:Radiopharmaceuticals; C027549:thallium chloride; D013793:Thallium